Skip to content
Products & Services · Total Revenues

Opdivo Qvantig — Total Revenues

Bristol-Myers Squibb Opdivo Qvantig — Total Revenues increased by 22.6% to $163M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1711.1%, from $9M to $163M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market penetration and clinical demand for the therapy, while a decrease may signal increased competition from biosimilars or newer therapeutic alternatives.

Detailed definition

This metric represents the total net sales generated by the Opdivo product line, a cornerstone of the company's immuno-o...

Peer comparison

Comparable to revenue metrics for flagship oncology blockbusters at peer pharmaceutical companies, such as Keytruda for Merck or Tecentriq for Roche.

Metric ID: bmy_segment_opdivo_qvantig_total_revenues

Historical Data

13 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0$0$0$0$0$0$0$0$9M$30M$67M$133M$163M
QoQ Change+233.3%+123.3%+98.5%+22.6%
YoY Change>999%
Range$0$163M
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Bristol-Myers Squibb's opdivo qvantig — total revenues?
Bristol-Myers Squibb (BMY) reported opdivo qvantig — total revenues of $163M in Q1 2026.
How has Bristol-Myers Squibb's opdivo qvantig — total revenues changed year-over-year?
Bristol-Myers Squibb's opdivo qvantig — total revenues increased by 1711.1% year-over-year, from $9M to $163M.
What does opdivo qvantig — total revenues mean?
The total revenue generated from sales of the Opdivo drug product.